Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OTLK Outlook Therapeutics, Inc.

交易中 08-14 11:22:41 EDT

0.7541

-0.1347

-15.16%

最高0.8438	最低0.7120	成交量5,074万
今开0.8400	昨收0.8888	日振幅14.83%
总市值1.41亿	流通市值1.22亿	总股本1.87亿
成交额3,893万	换手率31.47%	流通股本1.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.7541,"timestamp":1786720958745,"preClose":0.8888,"halted":0,"volume":50737472,"delay":0,"changeRate":-0.15155265526552658,"floatShares":161206747,"shares":187000000,"eps":-1.083111,"marketStatus":"交易中","change":-0.1347,"latestTime":"08-14 11:22:41 EDT","open":0.84,"high":0.8438,"low":0.712,"amount":38934474.773606405,"amplitude":0.14829,"askPrice":0.7542,"askSize":700,"bidPrice":0.7541,"bidSize":6000,"shortable":0,"etf":0,"ttmEps":-1.083111,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786737600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.8888,"preHourTrading":{"tag":"盘前","latestPrice":0.823,"preClose":0.8888,"latestTime":"09:29 EDT","volume":2280980,"amount":2024806.55767,"timestamp":1786714170380,"change":-0.0658,"changeRate":-0.074032,"amplitude":0.229523},"postHourTrading":{"tag":"盘后","latestPrice":0.87,"preClose":0.8888,"latestTime":"19:59 EDT","volume":695857,"amount":606995.389138,"timestamp":1786665587163,"change":-0.0188,"changeRate":-0.021152,"amplitude":0.031391},"volumeRatio":7.857622,"impliedVol":1.5713,"impliedVolPercentile":0.3984},"requestUrl":"/m/hq/s/OTLK/tweets","defaultTab":"tweets","newsList":[{"id":"1152377290","title":"Outlook Therapeutics公布2026财年第三季度财务业绩，并发布公司动态，重点强调FDA批准Lytenava™","url":"https://stock-news.laohu8.com/highlight/detail?id=1152377290","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152377290?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:17","pubTimestamp":1786706230,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 发布了2026财年第三季度的财务报告，同时更新了公司业务进展，其中核心亮点是Lytenava™已获得美国食品药品监督管理局（FDA）的批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173205729","title":"Outlook Therapeutics 终止与H.C. Wainwright的ATM发行协议，撤回2026年5月13日招股书补充文件——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1173205729","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173205729?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:04","pubTimestamp":1786565050,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.宣布，已正式终止其与H.C. Wainwright & Co., LLC签订的ATM发行协议。这一决定，伴随着对2026年5月13日相关招股说明书补充文件的撤回，已在最新提交给美国证券交易委员会的文件中明确披露。然而，Outlook Therapeutics并未在简短的文件中透露终止背后的具体原因，也未说明后续是否会寻求其他替代性融资渠道。回溯来看，这份最初于2026年5月13日生效的招股书补充文件，曾为公司与H.C. Wainwright的合作设定了明确的框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136247811","title":"Outlook Therapeutics 募资投向：助力Lytenava美国上市、补充运营资金及企业一般用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1136247811","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136247811?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:02","pubTimestamp":1786564929,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics 宣布，其最新融资所得将用于支持核心产品Lytenava在美国的上市推广，同时补充公司运营资本，并满足企业日常运营及一般性开支需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104353517","title":"Outlook Therapeutics 宣布 Lytenava™ 获 FDA 批准：成为首个且唯一用于治疗湿性 AMD 的眼用贝伐珠单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=1104353517","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104353517?lang=zh_cn&edition=full","pubTime":"2026-07-25 02:41","pubTimestamp":1784918495,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics 正式宣布，其药物 Lytenava™ 已获得美国食品药品监督管理局（FDA）批准。这是首款、也是唯一一款获 FDA 许可、专用于治疗湿性年龄相关性黄斑变性（湿性 AMD）的眼用贝伐珠单抗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166622993","title":"Outlook Therapeutics Inc：依据生物制品价格竞争与创新法案，预计享有12年市场独占期","url":"https://stock-news.laohu8.com/highlight/detail?id=1166622993","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166622993?lang=zh_cn&edition=full","pubTime":"2026-07-25 02:41","pubTimestamp":1784918469,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc：依据《生物制品价格竞争与创新法案》，该公司预计将获得长达12年的市场独占权。法案的庇护，意味着其产品在特定领域内将独享竞争壁垒，免受仿制生物制品的直接冲击。在专利丛林与法规迷宫中，如此明确的独占期，无疑为投资者与研发团队注入了一剂强心针。Outlook Therapeutics正站在这一历史性机遇的十字路口，其未来走向，值得密切追踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134726052","title":"Outlook Therapeutics宣布FDA接受其重新提交的Ons-5010/Lytenava™生物制剂许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1134726052","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134726052?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:02","pubTimestamp":1781611349,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 宣布，美国食品药品监督管理局已正式接受其针对湿性年龄相关性黄斑变性治疗药物Ons-5010/Lytenava™（Bevacizumab-Vikg）重新提交的生物制剂许可申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129840263","title":"Outlook Therapeutics宣布重新向美国FDA提交Ons-5010/Lytenava™ (Bevacizumab-Vikg)的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1129840263","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129840263?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:47","pubTimestamp":1780318050,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 已正式宣布，公司已重新向美国食品药品监督管理局（FDA）提交了其候选药物Ons-5010/Lytenava™ (贝伐珠单抗-Vikg)的生物制品许可申请（BLA）。此举标志着该药物在寻求监管批准以治疗湿性年龄相关性黄斑变性（wet AMD）的进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123921412","title":"Outlook Therapeutics宣布根据纳斯达克规则完成500万美元市场价注册直接发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1123921412","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123921412?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:00","pubTimestamp":1779998412,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 已公布其根据纳斯达克市场规则进行的注册直接发行的定价细节。此次发行总规模为500万美元，发行价格严格遵循\"按市价\"原则确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197521520","title":"Outlook Therapeutics完成FDA争议解决会议，Ons-5010最终裁决预计2026年5月揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1197521520","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197521520?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:06","pubTimestamp":1778875582,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 已成功完成针对其候选药物Ons-5010的美国食品药品监督管理局（FDA）争议解决会议。公司正积极推动该药物的审批进程，最终监管决定预计将于2026年5月公布。这一关键步骤标志着Ons-5010在寻求上市批准的道路上取得了重要进展，为后续的潜在商业化铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194394923","title":"Outlook Therapeutics公布2026财年第二季度财务业绩并发布公司最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1194394923","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194394923?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:06","pubTimestamp":1778875575,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 已正式发布其2026财年第二季度的财务报告，同时向市场提供了公司业务进展的最新情况。此次披露涵盖了公司在该财季内的关键财务数据与运营更新，旨在让投资者全面了解公司当前的发展状况与未来规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108219090","title":"Outlook Therapeutics与H.C. Wainwright签订ATM发行协议，融资额最高可达1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108219090","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108219090?lang=zh_cn&edition=full","pubTime":"2026-05-14 04:44","pubTimestamp":1778705058,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会提交的文件显示，生物制药公司Outlook Therapeutics, Inc.已与投资银行H.C. Wainwright & Co.签订了一项市场股票发行协议。根据该协议条款，Outlook Therapeutics将有权在特定时期内，通过H.C. Wainwright作为销售代理，不定期地发行和出售其普通股股票，以此筹集资金。此次ATM发行的总融资额度最高可达1亿美元。市场股票发行是一种灵活的融资工具，允许上市公司根据市场条件和自身资金需求，在既定额度内按现行市价向公众投资者出售新发行的股票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182483377","title":"Outlook Therapeutics宣布500万美元纳斯达克规则下市价定价注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1182483377","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182483377?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:30","pubTimestamp":1776861036,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.  今日披露了一项重要融资安排。该公司已达成协议，将通过注册直接发行的方式募集500万美元资金。此次发行定价严格遵循纳斯达克市场的相关规定，采用市价定价机制。这项融资举措标志着Outlook Therapeutics在资本运作方面迈出关键一步。根据纳斯达克规则，此次发行符合市场化定价原则。此次融资所得将用于推进公司核心管线的临床开发及一般营运资金需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107650089","title":"Outlook Therapeutics完成与FDA就ONS-5010/Lytenava™（贝伐珠单抗-Vikg）的联邦争议解决会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1107650089","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107650089?lang=zh_cn&edition=full","pubTime":"2026-04-21 21:06","pubTimestamp":1776776777,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc. (OTLK) 已顺利完成与美国食品药品监督管理局（FDA）针对眼科药物ONS-5010/Lytenava™（贝伐珠单抗-Vikg）的联邦争议解决（FDR）会议。此次关键性会议标志着该药物在寻求监管批准路径上的一个重要里程碑。公司正积极推动这一潜在疗法，旨在为湿性年龄相关性黄斑变性（wet AMD）患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164642417","title":"Outlook Therapeutics宣布FDA已受理关于Ons-5010/Lytenava™（贝伐珠单抗-Vikg）的正式争议解决申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1164642417","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164642417?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:50","pubTimestamp":1775566215,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.披露，美国食品药品监督管理局（FDA）已正式接受该公司针对其核心候选药物Ons-5010/Lytenava™（贝伐珠单抗-Vikg）所提交的正式争议解决请求。这一进展标志着公司在推动该眼科疗法获批的进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139966539","title":"Outlook Therapeutics完成500万美元公开发行募资","url":"https://stock-news.laohu8.com/highlight/detail?id=1139966539","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139966539?lang=zh_cn&edition=full","pubTime":"2026-03-26 04:07","pubTimestamp":1774469224,"startTime":"0","endTime":"0","summary":"新泽西州艾斯林2026年3月25日电——专注于提升视网膜疾病治疗标准生物制药企业Outlook Therapeutics, Inc.今日宣布，已完成此前公布的2000万股普通股及配套认股权证公开发行。每份认股权证可额外认购1股普通股，发行单元定价为0.25美元。认股权证行权价每股0.25美元，即日生效，有效期五年。本次发行扣除承销费用前的总收益为500万美元。若认股权证全部以现金行权，公司有望再获约500万美元资金注入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","BK4139","LENZ","BK4604","BK4099","BK4555","OTLK","TM","BK4007","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173210935","title":"Outlook Therapeutics公司利用新票据收益偿还旧债，现有票据本金及利息余额为1080万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173210935","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173210935?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664512,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics公司宣布将利用新发行票据所筹集的资金，用于偿还部分现有票据债务。经此操作后，该公司现有票据未偿还本金及利息余额仍达1080万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126487152","title":"Outlook Therapeutics将继续与FDA沟通 就确认性证据及后续路径寻求共识","url":"https://stock-news.laohu8.com/highlight/detail?id=1126487152","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126487152?lang=zh_cn&edition=full","pubTime":"2026-03-06 05:17","pubTimestamp":1772745431,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc.宣布，将持续与美国食品药品监督管理局（FDA）保持密切对话，旨在进一步明确监管机构对确认性证据要求的具体立场，并共同商定最合适的后续发展路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151191468","title":"Outlook Therapeutics与FDA就ONS-5010/Lytenava™（贝伐珠单抗-Vikg）召开A类会议后发布最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1151191468","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151191468?lang=zh_cn&edition=full","pubTime":"2026-03-06 05:15","pubTimestamp":1772745351,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.近日披露了与美国食品药品监督管理局就眼科药物ONS-5010/Lytenava举行A类会议后的关键动态。此次会议聚焦于该药物用于治疗湿性年龄相关性黄斑变性的监管路径，双方就后续申报策略达成重要共识。公司表示，与FDA的深入交流进一步明确了生物制品许可申请所需补充的数据要求及临床开发计划。此次沟通为ONS-5010/Lytenava的审评进程提供了更清晰的指引，有望加速其商业化进程。Outlook Therapeutics强调将继续与FDA保持密切协作，积极推进药物上市准备工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147633088","title":"Outlook Therapeutics合作推进欧洲商业化战略，Lytenava预计2027年在瑞士上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1147633088","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147633088?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:02","pubTimestamp":1771509746,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.通过合作伙伴关系加速其欧洲市场扩张计划，旗下创新药物Lytenava有望于2027年正式登陆瑞士市场。这一战略部署标志着公司在欧洲商业化布局取得重要进展，为未来业绩增长注入新动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178881233","title":"Outlook Therapeutics与Mediconsult Ag达成瑞士独家分销协议 扩大欧洲版图","url":"https://stock-news.laohu8.com/highlight/detail?id=1178881233","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178881233?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:02","pubTimestamp":1771509725,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.宣布与Mediconsult Ag签署独家商业分销协议，将旗下眼科药物Lytenava™（贝伐珠单抗γ）引入瑞士市场。这一战略合作标志着公司在欧洲业务布局的进一步扩展，有望提升其生物类似药产品在欧洲关键市场的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0861},{"period":"1month","weight":-0.4862},{"period":"3month","weight":2.8965},{"period":"6month","weight":0.8139},{"period":"1year","weight":-0.5827},{"period":"ytd","weight":-0.4375}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Outlook Therapeutics, Inc.于2010年1月5日在新泽西州注册成立。该公司是一家生物制药公司，在欧盟或欧盟、英国或英国率先获得ONS-5010/LYTENAVA（贝伐珠单抗-gamma）眼科制剂上市许可，用于治疗湿性年龄相关性黄斑变性，或湿性AMD。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0707},{"month":5,"riseRate":0.7,"avgChangeRate":0.330761},{"month":6,"riseRate":0.4,"avgChangeRate":0.075556},{"month":7,"riseRate":0.545455,"avgChangeRate":0.003223},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.17052},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Outlook Therapeutics, Inc.(OTLK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Outlook Therapeutics, Inc.(OTLK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}